(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 September 2015 (24.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/143091 A1

(51) International Patent Classification:
A61K 47/48 (2006.01) *C07K 16/32* (2006.01)
C07K 16/28 (2006.01) *C07K 16/40* (2006.01)

(21) International Application Number:
PCT/US2015/021342

(22) International Filing Date:
18 March 2015 (18.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/955,682 19 March 2014 (19.03.2014) US
62/061,556 8 October 2014 (08.10.2014) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors: **AVILA, Luis**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US). **PAN, Clark**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US). **QIU, Huawei**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US). **ZHOU, Qun**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US).

(74) Agents: **VELEMA, James, H.** et al.; Lathrop & Gage LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2015/143091 A1

(54) **Title**: SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES

(57) **Abstract**: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.